CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 30 enrolled
Drug / intervention
Alfliberceptdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03340610
NCT03340610Phase 4Completed
CompareCT.gov

Intravitreal Alflibercept Injection (IAI) for Persistent Diabetic Macular Edema (DME) After Treatment With Bevacizumab And Ranibizumab

Southeast Retina Center, Georgia·interventional·Posted Nov 13, 2017·Updated May 24, 2019

In Brief

A Phase 4 clinical trial evaluating Alflibercept for Diabetic Macular Edema. Completed, enrolled 30 participants across 1 site.

Detailed Summary

This is a phase 4 prospective, nonrandomized, open label, interventional clinical trial. Study eyes will receive 5 required initial monthly Intravitreal Aflibercept (IAI) doses of 2 mg followed by 2q8 IAI for a total of 52 weeks; only one study eye from each patient will be enrolled.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Macular Edema
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 13, 2017
Enrollment StartJun 1, 2015
Primary CompletionDec 1, 2018
Study CompletionDec 12, 2018
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 8.6 years ago

Interventions

Alfliberceptdrug

Intravitreal Injection